Skip to main content

News: Jorgen Mold PhD, BSc (Hons) joins Avance Clinical as Scientific Affairs Specialist

By September 13, 2020December 18th, 2023Company News

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to announce the appointment of Jorgen Mold PhD, BSc (Hons) as Scientific Affairs Specialist.

Jorgen has over 23 years of experience in medical research and drug development.

With a passion for developing new treatments for human diseases, Jorgen has worked in positions that span the full spectrum of a drug lifecycle from bench side discovery to post-market approval.

Prior to joining Avance Clinical, Jorgen worked in the Neurology Medical team at Merck Healthcare where his background in neuroimmunology and neuroinflammatory disorders was used to build strong scientific partnerships with key external stakeholders.

During this time, Jorgen also gained considerable knowledge of late-phase clinical development and regulatory submission. Prior to this, Jorgen was Director of Ion Channel Biology at Bionomics Limited, where he was responsible for leading the pre-clinical development of small molecule therapeutics for Multiple Sclerosis and Chronic pain.

Other notable career highlights include 5 years postdoctoral work in the department of Neurobiology at Northwestern University, Chicago working on Influenza Virus and a 3-year appointment at the Institute for Molecular Biosciences at the University of Queensland identifying novel peptides as pain therapeutics.

Jorgen has a PhD in medical sciences from the John Curtin School of Medical Research at the Australian National University and a Bachelor of Science (Hons) majoring in Biochemistry from the University of Queensland. Jorgen has published several peer-reviewed articles in prominent scientific journals and has contributed to numerous patents relating to small molecule therapeutics for the treatment of multiple sclerosis and chronic pain.

Leave a Reply


DOWNLOAD OUR LATEST WHITEPAPER

Why 65% of US Biotechs Struggle to Identify Suitable CRO Partner

By filling in this form you consent to Avance Clinical contacting you. Read our Privacy Policy
This field is for validation purposes and should be left unchanged.

This will close in 0 seconds